ALNY · Alnylam Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$165.04
+8.39 (+5.36%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$22.11B
Shares
133.94M
Volume · Nov 13
3.59M
Avg daily vol (3M)
2.04M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Alnylam Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Alnylam Pharmaceuticals, Inc. (ALNY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
Positive tone
340B reimbursement and site-of-care risk
Slower conversion of prescriber engagement into demand
Huntington's disease pipeline progress
Revenue
$1.46B
▲ 16.7% YoY Diluted EPS
$15.72
▲ 634.6% YoY Gross margin
75.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Alnylam Pharmaceuticals, Inc. (ALNY) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Alnylam Pharmaceuticals, Inc. (ALNY) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript
Confident tone
Amvutra TTR franchise performance
Triton-CM cardiovascular outcomes trial
Market size and disease awareness
Revenue
$1.29B
▲ 66.9% YoY Diluted EPS
$1.21
Gross margin
76.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Alnylam Pharmaceuticals, Inc. (ALNY) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Alnylam Pharmaceuticals, Inc. (ALNY) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Confident tone
TTR franchise growth and AMVUTTRA launch
Pipeline progress and RNAi platform
International TTR dynamics (Japan, Germany)
Revenue
$1.17B
▲ 96.4% YoY Diluted EPS
$1.51
Gross margin
82.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript
Confident tone
TTR franchise / Amvuttra launch
Alnylam 2030 strategic goals
Pipeline & R&D platform
Revenue
$1.10B*
▲ 84.9% YoY Gross margin
75.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript
Confident tone
AMVUTTRA cardiomyopathy (ATTR-CM) launch
TTR franchise revenue growth
International expansion (Japan, Germany, Europe)
Revenue
$1.25B
▲ 149.3% YoY Diluted EPS
$2.14
Gross margin
84.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
Confident tone
TTR franchise and ATTR-CM launch
Commercial revenue growth and guidance raise
Payer access and reimbursement
Revenue
$773.69M
▲ 17.3% YoY Diluted EPS
$-0.55
Gross margin
81.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Confident tone
TTR franchise and ATTR-CM launch
Pipeline and portfolio expansion
Access, payer dynamics and step edits
Revenue
$594.19M
▲ 20.2% YoY Diluted EPS
$-0.14
Gross margin
88.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript
Confident tone
TTR franchise commercial performance
ATTR cardiomyopathy launch
Pipeline and R&D
Revenue
$593.17M*
▲ 34.9% YoY Gross margin
82.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Confident tone
ATTR cardiomyopathy launch preparation
Pipeline expansion and CNS progress
TTR franchise growth
Revenue
$500.92M
▼ 33.3% YoY Diluted EPS
$-0.87
▼ 175.7% YoY Gross margin
83.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript
Confident tone
HELIOS-B Phase 3 results for vutrisiran in ATTR-CM
Commercial TTR franchise performance (AMVUTTRA/ONPATTRO)
Regulatory and pricing/ICER considerations
Revenue
$659.83M
▲ 107% YoY Diluted EPS
$-0.13
Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
Confident tone
TTR franchise / AMVUTTRA commercial performance
HELIOS-B Phase III readout
Zilebesiran hypertension program
Revenue
$494.33M
▲ 54.8% YoY Diluted EPS
$-0.52
Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript
Confident tone
TTR franchise growth (ONPATTRO/AMVUTTRA)
2024 financial guidance / P5x25 strategy
Competitive positioning vs tafamidis and eplontersen
Revenue
$439.72M*
▲ 31.2% YoY Gross margin
83.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2023 Earnings Call Transcript
Revenue
$750.53M
▲ 184% YoY Diluted EPS
$1.15
Gross margin
89.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2023 Earnings Call Transcript
Revenue
$318.75M
▲ 41.8% YoY Diluted EPS
$-2.21
Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2023 Earnings Call Transcript
Revenue
$319.29M
▲ 49.7% YoY Diluted EPS
$-1.40
Gross margin
87.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Call Transcript
Revenue
$335.04M*
▲ 29.6% YoY Gross margin
86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2022 Earnings Call Transcript
Revenue
$264.31M
▲ 40.9% YoY Diluted EPS
$-3.32
Gross margin
86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2022 Earnings Call Transcript
Revenue
$224.82M
▲ 1.9% YoY Diluted EPS
$-2.29
Gross margin
84.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2022 Earnings Call Transcript
Revenue
$213.26M
▲ 20.1% YoY Diluted EPS
$-2.00
Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-10
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2021 Earnings Call Transcript
Revenue
$258.54M*
▲ 58.1% YoY Gross margin
87.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2021 Earnings Call Transcript
Revenue
$187.63M
▲ 49.1% YoY Diluted EPS
$-1.72
Gross margin
85.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2021 Earnings Call Transcript
Revenue
$220.55M
▲ 112.1% YoY Diluted EPS
$-1.61
Gross margin
86.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2021 Earnings Call Transcript
Revenue
$177.57M
▲ 78.5% YoY Diluted EPS
$-1.71
Gross margin
87.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2020 Earnings Call Transcript
Revenue
$163.56M
▲ 128.2% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2020 Earnings Call Transcript
Revenue
$125.85M
▲ 79.6% YoY Diluted EPS
$-2.18
Gross margin
83.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2020 Earnings Call Transcript
Revenue
$103.96M
▲ 132.5% YoY Diluted EPS
$-1.56
Gross margin
82.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2020 Earnings Call Transcript
Revenue
$99.48M
▲ 198.8% YoY Gross margin
86.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2019 Earnings Call
Revenue
$71.68M
▲ 240.8% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
589 filings
542 filers
Visit website
Investor relations